All News
Targeting Autoantibodies in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis carries a high mortality rate and can be a management challenge. Moreover, exacerbations of IPF may be fatal. A multicenter uncontrolled study examined the utility of targeting autoantibody production with revealed surprising results.
Read Article
Frequency of Infliximab Infusion Reactions
A Canadian registry shows that in community-based infusion clinics, infusion reactions to IFX are uncommon and mild to moderate in nature.
Read Article
DSB: EULAR 2015 Safety Reports
Biologic Use Curtails Sepsis Events. An analysis of the German biologics register, RABBIT, examined the effect of current biologic therapy on future risk of sepsis (#OP0161).
Read Article
FDA News; Undeclared Dexamethasone Containing OTC Products
The FDA has issued public warnings that 4 over-the-counter products promoted for pain relief contain potentially harmful, undeclared dexamethasone. The supplements are Asihuri Plus Forte, Ginseng She Lian Wan, Jianbu Huqian Wan, and Saurean Fong Sep Lin.
Read Article
Gastroenterologists Use OTC Meds for GERD or Constipation
When gastroenterologists responded to a nationwide survey regarding their management of GERD and contipation, half of the 830 gastroenterology respondents (23% response rate) prescribed for their patients OTC proton-pump inhibitors (PPI), 13% recommended an OTC histamine-2&nbs
Read Article
The EULAR 2015 Report – Friday and Saturday
These abstracts and presentations were presented last week on the 12th and 13th of June at the EULAR 2015 annual meeting in Rome.
Read Article
Varicella Zoster Virus Commonly Found in Giant Cell Artery Biopsies
Varicella-zoster virus infection was studied in temporal artery biopsies from those suspected of having giant cell arteritis.
Read Article
The Risk of Uveitis in AS Treated with TNF Blockers
Claims data analysis of 2115 ankylosing spondylitis patients without uveitis who started TNF inhibitor therapy revealed that the median time to the onset of uveitis was longest for those taking adalimumab (243 days), followed by etanercept (182 days) and infliximab (144 days). 
Read Article
Expanding Global Biosimilar Market
Between 2010 and 2013, $95 billion in branded pharmaceutical patents will have expired, leading to significantly higher sales opportunities for those manufacturing generics and biosimilars.
Read Article
The EULAR 2015 Report- Friday
These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.
Read Article
The EULAR 2015 Report - Thursday
These abstracts and presentations were presented Thursday 11 June at the EULAR 2015 annual meeting.
Read Article
The EULAR 2015 Report - Wednesday
EULAR 2015 started the afternoon of Wednesday June 10th.
Read Article
Allopurinol Reduces Mortality in Gout
CVD risk is significantly augmented in gout. Choi and coworkers studied this issue using a UK general population database using an incident user cohort study with propensity score matching.
Read Article
High Flare Rates with Drug Withdrawal in JIA
While many adult rheumatologists are able to lessen or withdraw DMARD and biologic therapy in adults, little is known about the success of this practice in pediatric rheumatology clinics.
Read Article
Tofacitinib Equal to Etanercept in Psoriasis, but only at 10 mg bid Dose
A 12-week, phase III, non-inferiority, randomized clinical trial of tofacitinib, etanercept or placebo was conducted in 1106 patients with plaque psoriasis.
Read Article
Nonadherence to Self-Injected Biologics is High
Researchers from the University of Manchester investigated self-reported adherence to biologic treatment in RA and found that 41% of patients were non-adherent to adalimumab therapy at least once, and 23% were nonadherent overall. http://bit.ly/1KA2
Read Article
Amgen Halts Development of Brodalumab
IL-17 inhibitors are being developed for treatment of psoriasis, psoriatic arthritis and axial spondyloarthritis. Broadalumab has been in phase II & III trials and been developed by a partnership between Amgen and Astra-Zeneca.
Read Article
Sildenafil May Help Heal Scleroderma Ulcers
A prospective study of sildenafil was conducted in 25 centers that included 83 patients and 192 digital ulcers at entry. The odds of healing ulcers was less, but not significant, for sildenafil.
Read Article
RA Sarilumab Trials Meet Primary Endpoints
Three phase III studies of sarilumab (SARIL-RA-TARGET, -EASY and -ASCERTAIN), a fully-human IL6 receptor antibody, have been reported and met primary end points in these pivotal clinical trials.
Read Article
Amgen & Abbvie Increase the Price of TNF Inhibitors
The manufacturers of the 2 best selling TNF inhibitors, Enbrel and Humira, have announced a 9.9% price increase of May 1st. The current average price of Enbrel is $42,000 per annum.
Read Article